Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,825 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,211 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05879510 | 68Ga-NY104 PET/CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses | unknown | Phase 2 | 63 | Peking Union Medical College HospitalOTHER | 1 | Jul 13, 2023 | clinicaltrials |
| NCT05932719 | Multicentric Evaluation of COVID-19 Impact on Cancer Patients' Diagnostic and Management: Set-up of Indicators(COLLAT-COVID) | unknown | — | 4,000 | Hospices Civils de LyonOTHER | 1 |
| Jul 10, 2023 |
| clinicaltrials |
| NCT04445532 | Hepatobiliary Tumors Tissue Samples Acquisition | unknown | — | 450 | Peking Union Medical College HospitalOTHER | 1 | Jul 7, 2023 | clinicaltrials |
| NCT05932121 | Cross-sectional Case and Control Study on Quality of Life, Appearance and Functions in PTC Via Different Surgical Approach | unknown | — | 300 | Peking Union Medical College HospitalOTHER | 1 | Jul 6, 2023 | clinicaltrials |
| NCT05925413 | Cadonilimab Plus TACE in Patients With Intermediate-stage Unresectable Hepatocellular Carcinoma | unknown | Phase 2 | 41 | Eastern Hepatobiliary Surgery HospitalOTHER | 1 | Jun 29, 2023 | clinicaltrials |
| NCT01913717 | Short-term High Precision Radiotherapy for Early Prostate Cancer With Concomitant Boost on the Dominant Lesion | unknown | N/A | 65 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT02672449 | Carbon Ions Boost Followed by Pelvic Photon Radiotherapy for High Risk Prostate Cancer | unknown | N/A | 65 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT03427346 | Neoplastic Barrett Esophagus: Endoscopic Piecemeal vs. En Bloc Resection(BEEPER) | unknown | N/A | 407 | Universitätsklinikum Hamburg-EppendorfOTHER | 2 | Jun 28, 2023 | clinicaltrials |
| NCT03920488 | Next-Generation Sequencing-based Germline and Somatic Genetic Testing in Triple-negative Breast Cancer(PERSONA) | unknown | — | 264 | European Institute of OncologyOTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04797884 | Electromagnetic Fields Versus Placebo For Child-Pugh A and B Patients With Advanced Hepatocellular Carcinoma(ARTEMIS) | unknown | Phase 2 / Phase 3 | 166 | THERABIONIC INC.OTHER | 1 | Jun 28, 2023 | clinicaltrials |
| NCT04512833 | CyberKnife Stereotactic Body Radiation Therapy for Small Hepatocellular Carcinoma Patients With Decompensated Cirrhosis | unknown | — | 60 | Beijing 302 HospitalOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05897268 | Cryoablation Combined With Tislelizumab Plus Lenvatinib in 1L Treatment of Advanced HCC (CASTLE-10)(CASTLE-10) | unknown | Phase 2 | 25 | Fudan UniversityOTHER | 1 | Jun 27, 2023 | clinicaltrials |
| NCT05263219 | DEB-TACE+HAIC vs. HAIC for Large HCC | unknown | Phase 3 | 230 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05913583 | Correlation Between Pre-transplant ICI Exposure and Post-transplant Graft Rejection | unknown | — | 160 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 22, 2023 | clinicaltrials |
| NCT05910710 | Impact of Immuno-Oncologic Agent on Neoadjuvant Chemotherapy in Triple Negative Breast Cancer | unknown | — | 50 | Samsung Medical CenterOTHER | 1 | Jun 20, 2023 | clinicaltrials |
| NCT05908916 | Atezolizumab and Bevacizumab With Combined Radiotherapy for Advanced Hepatocellular Carcinoma | unknown | Phase 2 | 51 | Yonsei UniversityOTHER | 1 | Jun 18, 2023 | clinicaltrials |
| NCT05902377 | 68Ga-NY104 PET/CT Imaging in Renal Cell Carcinoma | unknown | Phase 2 | 46 | Peking Union Medical College HospitalOTHER | 1 | Jun 15, 2023 | clinicaltrials |
| NCT05903456 | Icaritin Soft Capsule Combined With Lenvatinib and TACE for the Treatment of Hepatocellular Carcinoma | unknown | Phase 2 | 20 | Zhejiang Cancer HospitalOTHER | 0 | Jun 15, 2023 | clinicaltrials |
| NCT05247346 | Early Detection of Cancer Onset Based on Sensing Field Cancerization at the Organ Level in the Alimentary Tract Using an Integrated Stimulated Raman/Scattering Modality for Endoscopic Real-time in Vivo Measurements(SENSITIVE) | unknown | N/A | 60 | University Medical Center GroningenOTHER | 1 | Jun 13, 2023 | clinicaltrials |
| NCT05527808 | A Single-arm Exploratory Study of Neoadjuvant Therapy | unknown | N/A | 28 | Jun LiuOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT05889949 | Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma | unknown | — | 200 | Sun Yat-sen UniversityOTHER | 1 | Jun 7, 2023 | clinicaltrials |
| NCT05886465 | HAIC Plus A+T for Patients With High-risk HCC: a Single-arm Phase 2 Trial | unknown | Phase 2 | 40 | Sun Yat-sen UniversityOTHER | 1 | Jun 2, 2023 | clinicaltrials |
| NCT03567720 | Tavo and Pembrolizumab With or Without Chemotherapy in Patients With Inoperable Locally Advanced or Metastatic TNBC | unknown | Phase 2 | 65 | OncoSec Medical IncorporatedINDUSTRY | 2 | Jun 1, 2023 | clinicaltrials |
| NCT04631731 | Risk Factors of Immune-ChEckpoint Inhibitors MEdiated Liver, Gastrointestinal, Endocrine and Skin Toxicity(ICEMELT) | unknown | Phase 1 / Phase 2 | 200 | Western Sydney Local Health DistrictOTHER | 1 | Jun 1, 2023 | clinicaltrials |
| NCT05393986 | Claudin18.2-redirected Chimeric Antigen Receptor T Cells With Co-expression of Cytokines in Solid Tumors | unknown | Phase 1 | 63 | Peking UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05703750 | Impact of Clinical Evident Portal Hypertension on HCC With TACE (CHANCE-CHESS 2301) | unknown | — | 228 | Zhongda HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05704192 | CT-based HVPG Assessment for Predicting the Prognosis of HCC With TACE (CHANCE-CHESS 2302) | unknown | — | 373 | Zhongda HospitalOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05883176 | TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria(B-TACE) | unknown | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | May 31, 2023 | clinicaltrials |
| NCT05879328 | The ImmunoXXL Study(ImmunoXXL) | unknown | — | 12 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 30, 2023 | clinicaltrials |
| NCT05754788 | Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis | unknown | — | 40 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 26, 2023 | clinicaltrials |
| NCT05302778 | Eribulin as a Second-line Treatment in Triple-negative Advanced Breast Cancer(HERMIONE-10) | unknown | — | 200 | University of Milano BicoccaOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05872412 | Effect of Platinum-based Versus Non-platinum-based Neoadjuvant Chemotherapy in Triple-negative Breast Cancer | unknown | Phase 2 | 82 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05875558 | M-TACE Treatment for Unresectable Hepatocellular Carcinoma | unknown | N/A | 40 | Shanghai Zhongshan HospitalOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05876052 | HOPE to Reduce Tumour Recurrence After LT In Patients With HCC(POTERE) | unknown | N/A | 192 | University of BolognaOTHER | 1 | May 25, 2023 | clinicaltrials |
| NCT05872841 | H101 Combined With TACE for Primary Hepatocellular Carcinoma With Portal Vein Thrombosis | unknown | Phase 2 | 38 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 24, 2023 | clinicaltrials |
| NCT05870696 | the Serum Metabolite Based PrecogColo Dx Test for Advanced Colorectal Neoplasia Screening | unknown | — | 2,000 | Peking University Third HospitalOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05870813 | CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer(CLEAR-B) | unknown | — | 3,000 | Institut fuer FrauengesundheitOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT05862181 | The Comparison Between HepaSphere Drug-eluting Bead Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma | unknown | — | 200 | Peking University Cancer Hospital & InstituteOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05868252 | Molecular Analysis of the Sloane Project | unknown | — | 1,500 | King's College LondonOTHER | 1 | May 22, 2023 | clinicaltrials |
| NCT05865730 | A Study of Oncobax®-AK in Patients With Advanced Solid Tumors | unknown | Phase 2 | 122 | EverImmuneINDUSTRY | 2 | May 19, 2023 | clinicaltrials |
| NCT05866172 | HAIC Combined Withzoledronic Acid for the Prevention of Bone Metastases in Advanced HCC | unknown | Phase 3 | 264 | Sun Yat-sen UniversityOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT04967495 | TACE Plus Multikinase Inhibitor and I-125 Seeds Brachytherapy for HCC With Branch PVTT | unknown | N/A | 171 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05763992 | Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial(BREAKFAST-2) | unknown | Phase 2 | 145 | Fondazione IRCCS Istituto Nazionale dei Tumori, MilanoOTHER | 1 | May 18, 2023 | clinicaltrials |
| NCT05859945 | Navigating the Clinical Trial Process for Hepatocellular Carcinoma | unknown | — | 500 | Power Life Sciences Inc.INDUSTRY | 0 | May 16, 2023 | clinicaltrials |
| NCT05831553 | TIP in Patients Affected by Metastatic TNBC(TIP) | unknown | — | 100 | Fondazione per la Medicina PersonalizzataOTHER | 1 | May 6, 2023 | clinicaltrials |
| NCT05839886 | The Adverse Event of Mitotane Therapy in Patients With Adrenocortical Carcinoma(MEET) | unknown | — | 50 | Shanghai Jiao Tong University School of MedicineOTHER | 0 | May 6, 2023 | clinicaltrials |
| NCT05843305 | A Study of BPI-452080 in Subjects With Solid Tumors | unknown | Phase 1 | 87 | Betta Pharmaceuticals Co., Ltd.INDUSTRY | 1 | May 6, 2023 | clinicaltrials |
| NCT04111029 | Liquid Biopsy in Hepatocellular Carcinoma(HCCGenePanel) | unknown | — | 30 | Post Graduate Institute of Medical Education and Research, ChandigarhOTHER | 1 | May 3, 2023 | clinicaltrials |
| NCT05837065 | Prognostic Models for HCC Based on Tumor Micronecrosis | unknown | — | 765 | Zhejiang UniversityOTHER | 1 | May 1, 2023 | clinicaltrials |
| NCT05134532 | Regorafenib After Progression on Atezolizumab Plus Bevacizumab in Advanced HCC(HCC) | unknown | Phase 2 | 40 | CHA UniversityOTHER | 1 | Apr 26, 2023 | clinicaltrials |
Data updated 23 days agoSource updated Jul 13, 2023source: clinicaltrials